You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
Name3,4-Methylenedioxyamphetamine
Accession NumberDB01509
TypeSmall Molecule
GroupsExperimental, Illicit
DescriptionAn amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem]
Structure
Thumb
Synonyms
Tenamfetamine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIXJZ28FJ27W
CAS number4764-17-4
WeightAverage: 179.2157
Monoisotopic: 179.094628665
Chemical FormulaC10H13NO2
InChI KeyInChIKey=NGBBVGZWCFBOGO-UHFFFAOYSA-N
InChI
InChI=1S/C10H13NO2/c1-7(11)4-8-2-3-9-10(5-8)13-6-12-9/h2-3,5,7H,4,6,11H2,1H3
IUPAC Name
1-(2H-1,3-benzodioxol-5-yl)propan-2-amine
SMILES
CC(N)CC1=CC2=C(OCO2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzodioxoles. These are organic compounds containing a benzene ring fused to either isomers of dioxole. Dioxole is a five-membered unsaturated ring of two oxygen atoms and three carbon atoms.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodioxoles
Sub ClassNot Available
Direct ParentBenzodioxoles
Alternative Parents
Substituents
  • Benzodioxole
  • Aralkylamine
  • Benzenoid
  • Oxacycle
  • Acetal
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9668
Caco-2 permeable+0.6011
P-glycoprotein substrateNon-substrate0.7169
P-glycoprotein inhibitor INon-inhibitor0.9117
P-glycoprotein inhibitor IINon-inhibitor0.9278
Renal organic cation transporterNon-inhibitor0.801
CYP450 2C9 substrateNon-substrate0.8661
CYP450 2D6 substrateNon-substrate0.6198
CYP450 3A4 substrateNon-substrate0.6464
CYP450 1A2 substrateInhibitor0.7625
CYP450 2C9 inhibitorNon-inhibitor0.8247
CYP450 2D6 inhibitorInhibitor0.7713
CYP450 2C19 inhibitorNon-inhibitor0.5475
CYP450 3A4 inhibitorNon-inhibitor0.7028
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5
Ames testNon AMES toxic0.6835
CarcinogenicityNon-carcinogens0.8578
BiodegradationReady biodegradable0.6509
Rat acute toxicity2.4882 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9589
hERG inhibition (predictor II)Non-inhibitor0.9386
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP1.64HANSCH,C & LEO,AJ (1985)
pKa9.67 (at 25 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility2.83 mg/mLALOGPS
logP1.15ALOGPS
logP1.43ChemAxon
logS-1.8ALOGPS
pKa (Strongest Basic)10.01ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.48 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity49.47 m3·mol-1ChemAxon
Polarizability19.51 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
AcepromazineAcepromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
AceprometazineAceprometazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
AcetazolamideAcetazolamide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
AcetophenazineAcetophenazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Acrivastine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Acrivastine.
Alcaftadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Alcaftadine.
Alfentanil3,4-Methylenedioxyamphetamine may increase the analgesic activities of Alfentanil.
Alimemazine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Alimemazine.
Alphacetylmethadol3,4-Methylenedioxyamphetamine may increase the analgesic activities of Alphacetylmethadol.
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Aluminum phosphateAluminum phosphate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
AmineptineAmineptine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
AmisulprideAmisulpride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
AmitriptylineAmitriptyline may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Ammonium chlorideThe serum concentration of 3,4-Methylenedioxyamphetamine can be decreased when it is combined with Ammonium chloride.
AmperozideAmperozide may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Antazoline3,4-Methylenedioxyamphetamine may decrease the sedative activities of Antazoline.
AripiprazoleAripiprazole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
AsenapineAsenapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Astemizole3,4-Methylenedioxyamphetamine may decrease the sedative activities of Astemizole.
AzaperoneAzaperone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Azatadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Azatadine.
Azelastine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Azelastine.
BenmoxinBenmoxin may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
Bezitramide3,4-Methylenedioxyamphetamine may increase the analgesic activities of Bezitramide.
BifeprunoxBifeprunox may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Brompheniramine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Brompheniramine.
Buclizine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Buclizine.
Buprenorphine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Buprenorphine.
Butanoic Acid3,4-Methylenedioxyamphetamine may decrease the sedative activities of Butanoic Acid.
Butorphanol3,4-Methylenedioxyamphetamine may increase the analgesic activities of Butorphanol.
Calcium carbonateCalcium carbonate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Carbinoxamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Carbinoxamine.
Carfentanil3,4-Methylenedioxyamphetamine may increase the analgesic activities of Carfentanil.
CariprazineCariprazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
CaroxazoneCaroxazone may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
Cetirizine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Cetirizine.
Chloropyramine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Chloropyramine.
Chlorphenamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Chlorphenamine.
Chlorphenoxamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Chlorphenoxamine.
ChlorpromazineChlorpromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Cimetidine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Cimetidine.
Cinnarizine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Cinnarizine.
Clemastine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Clemastine.
ClomipramineClomipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
ClozapineClozapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Codeine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Codeine.
CyamemazineCyamemazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Cyclizine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Cyclizine.
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Cyproheptadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Cyproheptadine.
DapiprazoleDapiprazole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
DesipramineDesipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Desloratadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Desloratadine.
Dexbrompheniramine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dexbrompheniramine.
Dexchlorpheniramine maleate3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.
Dextromoramide3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dextromoramide.
Dextropropoxyphene3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dextropropoxyphene.
Dezocine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dezocine.
DiclofenamideDiclofenamide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Dihydrocodeine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dihydrocodeine.
Dihydroetorphine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dihydroetorphine.
Dihydromorphine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dihydromorphine.
Dimenhydrinate3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dimenhydrinate.
Dimetindene3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dimetindene.
Dimetotiazine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dimetotiazine.
Diphenhydramine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Diphenhydramine.
Diphenoxylate3,4-Methylenedioxyamphetamine may increase the analgesic activities of Diphenoxylate.
DosulepinDosulepin may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Doxepin3,4-Methylenedioxyamphetamine may decrease the sedative activities of Doxepin.
DoxepinDoxepin may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Doxylamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Doxylamine.
DPDPE3,4-Methylenedioxyamphetamine may increase the analgesic activities of DPDPE.
DroperidolDroperidol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Emedastine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Emedastine.
Epinastine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Epinastine.
Esmirtazapine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Esmirtazapine.
EsmirtazapineEsmirtazapine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Ethopropazine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Ethopropazine.
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with 3,4-Methylenedioxyamphetamine.
EthoxzolamideEthoxzolamide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Ethylmorphine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Ethylmorphine.
Etorphine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Etorphine.
Famotidine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Famotidine.
FencamfamineFencamfamine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Fentanyl3,4-Methylenedioxyamphetamine may increase the analgesic activities of Fentanyl.
Fexofenadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Fexofenadine.
Flunarizine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Flunarizine.
FlupentixolFlupentixol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
FluphenazineFluphenazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
FluspirileneFluspirilene may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
FurazolidoneFurazolidone may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
GuanethidineThe serum concentration of 3,4-Methylenedioxyamphetamine can be decreased when it is combined with Guanethidine.
HaloperidolHaloperidol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Heroin3,4-Methylenedioxyamphetamine may increase the analgesic activities of Heroin.
HexamethylenetetramineThe serum concentration of 3,4-Methylenedioxyamphetamine can be decreased when it is combined with Hexamethylenetetramine.
HydracarbazineHydracarbazine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
Hydrocodone3,4-Methylenedioxyamphetamine may increase the analgesic activities of Hydrocodone.
Hydromorphone3,4-Methylenedioxyamphetamine may increase the analgesic activities of Hydromorphone.
Hydroxyzine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Hydroxyzine.
IloperidoneIloperidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
ImipramineImipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Ioflupane I-1233,4-Methylenedioxyamphetamine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideIproclozide may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
IproniazidIproniazid may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
IsocarboxazidIsocarboxazid may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
Isothipendyl3,4-Methylenedioxyamphetamine may decrease the sedative activities of Isothipendyl.
Ketobemidone3,4-Methylenedioxyamphetamine may increase the analgesic activities of Ketobemidone.
Ketotifen3,4-Methylenedioxyamphetamine may decrease the sedative activities of Ketotifen.
L-Glutamic AcidThe serum concentration of 3,4-Methylenedioxyamphetamine can be decreased when it is combined with L-Glutamic Acid.
Levocabastine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Levocabastine.
Levocetirizine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Levocetirizine.
Levomethadyl Acetate3,4-Methylenedioxyamphetamine may increase the analgesic activities of Levomethadyl Acetate.
Levorphanol3,4-Methylenedioxyamphetamine may increase the analgesic activities of Levorphanol.
LithiumLithium may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Lodoxamide3,4-Methylenedioxyamphetamine may decrease the sedative activities of Lodoxamide.
Lofentanil3,4-Methylenedioxyamphetamine may increase the analgesic activities of Lofentanil.
Loratadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Loratadine.
LoxapineLoxapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
LurasidoneLurasidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
MagaldrateMagaldrate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium carbonateMagnesium carbonate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium oxideMagnesium oxide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
MebanazineMebanazine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
Meclizine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Meclizine.
MelperoneMelperone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Mepyramine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Mepyramine.
Mequitazine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Mequitazine.
MesoridazineMesoridazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Methadone3,4-Methylenedioxyamphetamine may increase the analgesic activities of Methadone.
Methadyl Acetate3,4-Methylenedioxyamphetamine may increase the analgesic activities of Methadyl Acetate.
Methapyrilene3,4-Methylenedioxyamphetamine may decrease the sedative activities of Methapyrilene.
MethazolamideMethazolamide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Methylene blueMethylene blue may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
Metiamide3,4-Methylenedioxyamphetamine may decrease the sedative activities of Metiamide.
Mianserin3,4-Methylenedioxyamphetamine may decrease the sedative activities of Mianserin.
MinaprineMinaprine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
Mirtazapine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Mirtazapine.
MirtazapineMirtazapine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
MoclobemideMoclobemide may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
MolindoneMolindone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Morphine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Morphine.
Nalbuphine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Nalbuphine.
NialamideNialamide may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
Nizatidine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Nizatidine.
Normethadone3,4-Methylenedioxyamphetamine may increase the analgesic activities of Normethadone.
NortriptylineNortriptyline may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
OctamoxinOctamoxin may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
OlanzapineOlanzapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Olopatadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Olopatadine.
OndansetronOndansetron may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Opium3,4-Methylenedioxyamphetamine may increase the analgesic activities of Opium.
OsanetantOsanetant may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Oxycodone3,4-Methylenedioxyamphetamine may increase the analgesic activities of Oxycodone.
Oxymorphone3,4-Methylenedioxyamphetamine may increase the analgesic activities of Oxymorphone.
PaliperidonePaliperidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
PargylinePargyline may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
Pemirolast3,4-Methylenedioxyamphetamine may decrease the sedative activities of Pemirolast.
Pentazocine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Pentazocine.
PerospironePerospirone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
PerphenazinePerphenazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Pethidine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Pethidine.
PhenelzinePhenelzine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
Phenindamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Phenindamine.
PheniprazinePheniprazine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
Pheniramine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Pheniramine.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with 3,4-Methylenedioxyamphetamine.
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with 3,4-Methylenedioxyamphetamine.
PimozidePimozide may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
PipamperonePipamperone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
PipotiazinePipotiazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
PirlindolePirlindole may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
PivhydrazinePivhydrazine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
ProchlorperazineProchlorperazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
PromazinePromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Promethazine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Promethazine.
PropericiazinePropericiazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
ProtriptylineProtriptyline may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
QuetiapineQuetiapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Ranitidine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Ranitidine.
RasagilineRasagiline may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
Remifentanil3,4-Methylenedioxyamphetamine may increase the analgesic activities of Remifentanil.
RemoxiprideRemoxipride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
ReserpineReserpine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
RisperidoneRisperidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Roxatidine acetate3,4-Methylenedioxyamphetamine may decrease the sedative activities of Roxatidine acetate.
SafrazineSafrazine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
SelegilineSelegiline may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
SertindoleSertindole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Spaglumic Acid3,4-Methylenedioxyamphetamine may decrease the sedative activities of Spaglumic Acid.
Sufentanil3,4-Methylenedioxyamphetamine may increase the analgesic activities of Sufentanil.
SulpirideSulpiride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Tapentadol3,4-Methylenedioxyamphetamine may increase the analgesic activities of Tapentadol.
Terfenadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Terfenadine.
Tesmilifene3,4-Methylenedioxyamphetamine may decrease the sedative activities of Tesmilifene.
ThioproperazineThioproperazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
ThioridazineThioridazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
ThiothixeneThiothixene may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Thonzylamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Thonzylamine.
TianeptineTianeptine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
ToloxatoneToloxatone may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
Tramadol3,4-Methylenedioxyamphetamine may increase the analgesic activities of Tramadol.
Tranilast3,4-Methylenedioxyamphetamine may decrease the sedative activities of Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
TranylcypromineTranylcypromine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
TriflupromazineTriflupromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
TrimipramineTrimipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Tripelennamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Tripelennamine.
Triprolidine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Triprolidine.
Vitamin CThe serum concentration of 3,4-Methylenedioxyamphetamine can be decreased when it is combined with Vitamin C.
ZiprasidoneZiprasidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
ZotepineZotepine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
Food InteractionsNot Available
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:10 / Updated on August 17, 2016 12:23